1 -- 1 of 40 -- 1st Quarter 2020 Earnings Call April 14, 2020 -- 2 of 40 -- Cautionary Note on Forward-looking Statements 3 This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to our business, or on our ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com. -- 3 of 40 -- Strategic Partnerships, Collaborations & Licensing Arrangements 4 During the course of this morning’s presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation, and TREMFYA discovered using MorphoSys AG antibody technology Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA includes technology licensed from Alkermes Pharma Ireland Limited Infectious Diseases PREZCOBIX/ REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA developed in collaboration with ViiV Healthcare UK Cardiovascular/ Metabolism/Other INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation, XARELTO co-developed with Bayer HealthCare AG, PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Oncology IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company, ZYTIGA licensed from BTG International Ltd., VELCADE developed in collaboration with Millennium: The Takeda Oncology Company, DARZALEX licensed from Genmab A/S, BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc., and cusatuzumab licensed and developing in collaboration argenx BVBA and argenx SE Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan -- 4 of 40 -- CEO Perspective on COVID-19 COVID-19 Vaccine Update Sales Performance and Earnings Review Capital Allocation and Guidance Q&A 5 Agenda 1 2 3 4 5 Joseph J. Wolk Executive Vice President, Chief Financial Officer Chris DelOrefice Vice President, Investor Relations Alex Gorsky Chairman and Chief Executive Officer Paul Stoffels, M.D. Vice Chairman of the Executive Committee & Chief Scientific Officer Joaquin Duato Vice Chairman of the Executive Committee -- 5 of 40 -- -- 6 of 40 -- of dividend increases consecutive years 58 Inclusive of the April 2020 dividend declaration 7 -- 7 of 40 -- 8 8 -- 8 of 40 -- Commitment to Support Frontline Health Workers over 10 years $250M Plus an additional $50M 9 -- 9 of 40 -- Medical Devices Consumer Health Pharmaceuticals 10 -- 10 of 40 -- Pharmaceuticals Consumer Health 11 -- 11 of 40 -- 12 Medical Devices -- 12 of 40 -- Unparalleled Scientific Expertise Lead COVID-19 vaccine candidate Available for emergency use in early 2021 13 -- 13 of 40 -- 14 14 -- 14 of 40 -- 15 -- 15 of 40 -- We have mobilized a multi-pronged response to COVID-19 Developing a vaccine leveraging our proven Ad26 and Per.C6 platforms Screening our late-stage and marketed antiviral compound library, other companies’ compound libraries to identify broad spectrum of drugs Exploring immuno-modulators to protect against the over-active immune response we see in some patients 16 Unprecedented global health crisis > 1.6 MM cases > 100,000 deaths* A vaccine is critical to eradicating the pandemic * As of 4/10/20 https://coronavirus.jhu.edu/map.html -- 16 of 40 -- 17 Key attributes of Prioritization WHO – Geneva – Jan 2020 Vectored DNA RNA J&J Vaccine 1 dose regimen Neutralizing antibodies Proven strategy Cytokine CMI response Risk of enhancement  Speed of development Capability to scale up Duration of immunity Vaccine stability Cost/dose Key attributes of Janssen vaccine platform position us for leadership Fulfilled according to WHO Fulfilled based on Janssen data Either unfulfilled (WHO) or unavailability of relevant data WHO criteria for vaccine platform Ad26® vector technology: potent, long-lasting cellular and humoral immunity Low or no risk of “Enhanced Respiratory Disease” Well tolerated safety profile >50,000 people, and absence of any safety signal PER.C6® cell line: high yields, scalable, fully industrialized Favorable thermostability profile (>2 years at 2-8°C) Distribution using existing infrastructure -- 17 of 40 -- 18 Designing a vaccine Create multiple candidates Select a lead candidate COVID-19 Adenovirus Snipping of spike protein Injection of spike protein into Adenovirus • January 2020: SARS-CoV-2 sequence available • Vaccine design commences • SARS-CoV-2 spike protein inserted into Ad26 vector • Multiple vaccine candidates constructed • March 2020: Validated with pre-clinical testing to identify lead candidate January – March 2020 -- 18 of 40 -- September 2020 Start FIH study Road to the Janssen vaccine: Accelerating R&D and manufacturing in parallel to get to 1B doses 19 Q1 2021 Research & development, upscaling, clinical testing Select lead vaccine candidate Vaccine available Q4 2020 Expanding manufacturing capabilities June 2020 Transfer of Master Seed / pre-manufacturing December 2020 Data available Q1 2021 First batches of vaccines available for emergency use authorization External partnerships March 30, 2020 Announced lead vaccine candidate Q1 2020 Q2 2020 Q3 2020 -- 19 of 40 -- Regional Sales Results Q1 2020 Q1 2019 % CHANGE Reported Operational1 U.S. $10.7 $10.1 5.6% 5.6% Europe 4.8 4.6 4.7 7.5 Western Hemisphere (ex U.S.) 1.5 1.5 (0.1) 8.5 Asia-Pacific, Africa 3.7 3.8 (3.1) (1.9) International 10.0 9.9 1.0 4.0 Worldwide (WW) $20.7 $20.0 3.3% 4.8% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Note: Values may not add due to rounding 1st Quarter 2020 Sales Dollars in Billions 20 -- 20 of 40 -- 9.5%; 10.5%1 Q1 2020 Q1 2019 $2.30 $2.10 1st Quarter 2020 Financial Highlights Dollars in Billions, except EPS Reported %; Operational %1 21 Sales Adjusted Earnings2 Adjusted EPS2 3.3%; 4.8%1 $20.7 $20.0 GAAP Earnings 54.6% $5.8 $3.7 8.7% Q1 2020 Q1 2019 GAAP EPS 56.1% $2.17 $1.39 Q1 2020 Q1 2020 Q1 2019 Q1 2019 Q1 2020 Q1 2019 $6.2 $5.7 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website -- 21 of 40 -- Baby Care $361 Skin Health/Beauty $1,117 Women's Health $232 OTC $1,348 Wound Care/Other $171 Oral Care $395 $3,625 9.2%, 11.3% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Consumer Health Highlights – 1st Quarter 2020 Solid growth across multiple franchises 22 Key Drivers of Operational Performance1 Baby Care • Decline due to Baby Center divestiture, SKU rationalization and COVID-19 related impacts in EMEA and ASPAC, partially offset by strength in AVEENO baby Skin Health/ Beauty • Primarily due to U.S. NEUTROGENA growth in e-commerce, warehouse club as well as Hydroboost promotional timing and strength in EMEA; AVEENO and OGx higher market demand due to COVID-19 partially offset by declines due to COVID-19 impacts in China and Japan Oral Care • Primarily due to market growth for LISTERINE mouthwash due to increased demand related to COVID-19 as well as new U.S. product innovation OTC • U.S.: Due to market growth driven by COVID-19, a strong flu and allergy season and overall share gains as well as competitive supply disruptions and ZARBEE’s NATURALS strength • OUS: Primarily due to COVID-19 impact, stronger cough and cold season in EMEA and ASPAC Women’s Health • Driven by o.b. increased COVID-19 demand in Germany and growth in napkins primarily in LATAM Wound Care/Other • Primarily due to U.S. market growth in NEOSPORIN and adhesive bandages due to increased demand related to COVID-19 Adjusted Operational Sales2: WW 11.0%, U.S. 21.7%, Int’l 2.8% Reported: WW 9.2%, U.S. 21.0%, Int’l 0.3% Operational1: WW 11.3%, U.S. 21.0%, Int’l 3.9% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 2.5%, 3.5% (8.2)%, (4.9)% 10.7%, 11.8% 24.1%, 25.8% 7.6%, 9.8% 2.9%, 9.2% -- 22 of 40 -- Key Drivers of Operational Performance1 Immunology • Growth driven by strong uptake of STELARA in Crohn’s Disease and increased COVID-19 related demand, strength in TREMFYA in Psoriasis, and expanded indications of SIMPONI ARIA, and U.S. immunology market growth • REMICADE decline due to increased discounts/rebates and biosimilar competition Infectious Diseases • Strong sales of SYMTUZA and increased COVID-19 demand across the Infectious Disease portfolio, partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and PREZISTA OUS LOE Neuroscience • Paliperidone long-acting injectables growth due to strength of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts and persistency, partially offset by cannibalization of RISPERDAL CONSTA and generic competition on CONCERTA Oncology • DARZALEX continued strong market growth and share gains in the U.S. and EU, driven by patient uptake in all lines of therapy • Strong sales of IMBRUVICA due to increased patient uptake globally, higher market share primarily in CLL L1, and increased COVID-19 demand related to longer scrips being written • Strong sales and share growth of ZYTIGA in the EU and ASPAC, partially offset by lower sales in the U.S. due to generic competition • Launch uptake of ERLEADA and share gains in non-metastatic CRPC as well as recently approved mCSPC indication; available in 18 EMEA countries • Lower sales of VELCADE due to generic competition Cardiovascular/ Metabolism/ Other (CVM/Other) • Decline in XARELTO due to increased rebates including channel mix dynamics, partially offset by market growth and increased COVID-19 demand due to longer scrips being written • INVOKANA/INVOKAMET lower sales due to share loss from competitive pressures and safety label update in the U.S., slightly offset by growth in EU and LATAM • Lower sales of PROCRIT/EPREX due to biosimilar competition Pulmonary Hypertension (PH) • Growth in OPSUMIT and UPTRAVI due to continued share gains, market growth, and increased COVID-19 related demand • Lower sales of TRACLEER due to generic competition and cannibalization from OPSUMIT Adjusted Operational Sales2: WW 10.2%, U.S. 8.7%, Int’l 12.0% Immunology $3,638 Infectious Diseases $920 Neuroscience $1,658 Oncology $3,013 CVM/Other $1,160 PH $745 $11,134 8.7%, 10.1% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Pharmaceutical Highlights – 1st Quarter 2020 Strong growth across multiple therapeutic areas 23 Reported: WW 8.7%, U.S. 8.6%, Int’l 8.8% Operational1: WW 10.1%, U.S. 8.6%, Int’l 12.0% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding (13.8)%, (13.1)% 13.7%, 14.7% 19.7%, 21.8% 1.8%, 3.1% 8.7%, 11.0% 11.9%, 13.1% -- 23 of 40 -- Orthopaedics $2,038 Surgery $2,100 Vision $1,067 Interventional Solutions $727 $5,932 (8.2)%, (6.9)% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Medical Devices Highlights – 1st Quarter 2020 Sales decline driven by the negative impact of COVID-19 24 Reported: WW (8.2)%, U.S. (6.8)%, Int’l (9.4)% Operational1: WW (6.9)%, U.S. (6.8)%, Int’l (6.9)% Key Drivers of Operational Performance1 Interventional Solutions • Growth driven by Atrial Fibrillation procedure growth coupled with strong diagnostic catheter sales and new products partially offset by the net negative impact of COVID-19 Orthopaedics • Hips: Driven by the net negative impact of COVID-19 partially offset by leadership position in the anterior approach, strong market demand for the ACTIS stem and enabling technologies - KINCISE and VELYS Hip Navigation • Knees: Driven by the negative impact of COVID-19 partially offset by the continued global uptake of new products • Trauma: Driven by the negative impact of COVID-19 and market softness • Spine, Sports & Other: Driven by the negative impact of COVID-19 and base business declines in Spine partially offset by OUS share growth in Sports • Spine: WW: ~(11%), U.S.: ~(8%), OUS: ~(14%) Surgery • Advanced: • Endocutters: ~(6%) Driven by the negative impact of COVID-19 and competitive pressures in the U.S. partially offset by the growth of new products in ASPAC • Biosurgery: ~FLAT as the negative impact of COVID-19 was offset by the growth of new products • Energy: ~FLAT as the negative impact of COVID-19 and competitive pressures in the U.S. was offset by new product growth OUS • General: Driven by the ASP divestiture and the negative impact of COVID-19 Vision • Contact Lenses/Other: Net negative impact of COVID-19 offset by double-digit U.S. growth in daily disposable lenses in the ACUVUE OASYS family • Surgical: Primarily driven by negative impact of COVID-19 and competitive pressures in the U.S. partially offset by new product growth OUS Adjusted Operational Sales2: WW (4.8)%, U.S. (4.3)%, Int’l (5.3)% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding (0.6)%, 0.4% (5.5)%, (4.5)% (7.5)%, (6.5)% (12.3)%, (10.5)% -- 24 of 40 -- 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 General Surgery now includes Specialty Surgery Note: Values may not add due to rounding Medical Devices Highlights – 1st Quarter 2020 Sales decline driven by the negative impact of COVID-19 25 Surgery Orthopaedics Vision Care Contact Lenses/Other Advanced General2 Hips Knees Trauma Spine, Sports & Other Surgical $814 (1.3)%, (0.3)% $253 (16.9)%, (15.9)% $948 (3.3)%, (1.4)% $1,153 (18.5)%, (16.8)% $337 (6.7)%, (5.6)% $343 (7.0)%, (6.1)% $654 (4.5)%, (3.5)% $703 (10.7)%, (9.8)% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Vision $1,067 (5.5)%, (4.5)% Orthopaedics $2,038 (7.5)%, (6.5)% Surgery $2,100 (12.3)%, (10.5)% -- 25 of 40 -- Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 26 2020 2019 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $20,691 100.0 $20,021 100.0 3.3 Cost of products sold 7,062 34.1 6,615 33.0 6.8 Gross Profit 13,629 65.9 13,406 67.0 1.7 Selling, marketing, and administrative expenses 5,203 25.1 5,219 26.1 (0.3) Research and development expense 2,580 12.5 2,858 14.3 (9.7) In-process research and development - - 890 4.4 Interest (income) expense, net (42) (0.2) 3 0.0 Other (income) expense, net (679) (3.3) (22) (0.1) Restructuring 58 0.3 36 0.2 Earnings before provision for taxes on income 6,509 31.5 4,422 22.1 47.2 Provision for taxes on income 713 3.5 673 3.4 5.9 Net Earnings $5,796 28.0 $3,749 18.7 54.6 - Net earnings per share (Diluted) $2.17 $1.39 56.1 Average shares outstanding (Diluted) 2,671.0 2,698.8 Effective tax rate 11.0% 15.2% . Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $7,244 35.0 $6,867 34.3 5.5 Net earnings $6,154 29.7 $5,661 28.3 8.7 Net earnings per share (Diluted) $2.30 $2.10 9.5 Effective tax rate 15.0% 17.6% 1st Quarter 2020 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 26 of 40 -- Adjusted Income Before Tax by Segment1 1st Quarter 2020 27 Pharmaceutical Medical Devices Consumer Health Expenses Not Allocated to Segments 1Q 2020 1Q 2019 Pharmaceutical 45.3% 41.7% Medical Devices 24.2% 29.6% Consumer 24.5% 25.0% Total 35.0% 34.3% 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 4/14/2020 Note: Values may not add due to rounding % to Sales 2 -- 27 of 40 -- Pharmaceuticals • Regulatory Approvals: – STELARA (ustekinumab) – European Commission (EC) approval of expanded use for the treatment of pediatric patients (ages 6–11) with moderate to severe plaque psoriasis – ERLEADA (apalutamide) – EC granted marketing authorization for the expanded use to include the treatment of adult men with metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy • Regulatory Submissions: – DARZALEX (daratumumab) – Submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for the combination with carfilzomib and dexamethasone (DKd) for relapsed/refractory multiple myeloma – Ponesimod – Submission of a supplemental New Drug Application to the FDA and marketing authorization application to the European Medicines Agency (EMA) for the treatment of adult patients with relapsing multiple sclerosis • Other: – JNJ-6372 – FDA granted Breakthrough Therapy Designation for the treatment of non-small cell lung cancer – Rilpivirine and cabotegravir 48-week results of phase 3b ATLAS study demonstrate the safety and efficacy of long-acting injectable HIV treatment administered every two months – Rilpivirine and cabotegravir results of phase 3 FLARE study demonstrate the safety and efficacy of long-acting injectable HIV treatment regimen through 96 weeks – XARELTO (rivaroxaban) – Landmark phase 3 VOYAGER PAD study of XARELTO plus aspirin shows significant benefit in patients with symptomatic peripheral artery disease after lower-extremity revascularization – Announced lead COVID-19 vaccine candidate and landmark new partnership with U.S. Department of Health & Human Services – Launched HEARTLINE, the first-of-its-kind, virtual study designed to explore if a new iPhone app and Apple Watch can help reduce the risk of stroke – RPGR gene therapy – EMA has granted both Priority Medicines and Advanced Therapy Medicinal Product designations for the treatment of inherited retinal disease X-linked retinitis pigmentosa Notable New Announcements in 1st Quarter 20201 28 1 These developments and all other news releases are available online in the Investors section of the company’s website at news releases -- 28 of 40 -- -- 29 of 40 -- Business Continuity 30 Robust business continuity plans across our network Commercial Capabilities Support healthcare providers virtually and directly engage in areas needed Research & Development Maintain our clinical operation priorities, protecting the participants and satisfying all regulatory requirements Manufacturing Closely monitor and maintain critical inventory Most broadly-based global healthcare company with sustainable and resilient business model -- 30 of 40 -- Capital Allocation Strategy Capital Allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases HIGHER PRIORITY LOWER PRIORITY Investment in M&A Dollars in Billions Q1 2020 Cash and Marketable Securities $18.1 Debt ($27.6) Net Debt ($9.5) Free Cash Flow2 ~$3.0 Q1 2020: $2.6B invested in R&D $2.5B in dividends paid to shareholders Note: values may have been rounded 1 Non-GAAP measure; cash flow from operations less CAPEX 2 Estimated as of April 14, 2020 31 -- 31 of 40 -- • Smaller levels of disruption associated with delayed diagnosis and new patient starts • Continued above market growth • Continue to progress our plans for our 2020 anticipated filings and approvals 32 2020 Guidance Assumptions Pharmaceutical • Expect key categories such as OTC to continue to perform well • Impact to certain categories as a result of reduced store traffic and social distancing behaviors • Above market growth in the U.S. • SKU rationalization program for benchmark profitability Consumer Health Enterprise • Inclusive of the macroeconomic impact of COVID-19 • The relative shape of the COVID-19 curve to be an acute, shorter term impact • Virus does not return in the fall at the same intensity levels we are currently experiencing • Recovery for procedures begins at the end of the 2nd quarter, continues in the 3rd quarter and improves further in the 4th quarter -- 32 of 40 -- Medical Devices: COVID-19 Framework 33 Q1 Q2 Q3 Q4 Initial Impact Significant Impact Stabilization Recovery -- 33 of 40 -- Medical Devices: COVID-19 Framework • Q1 actual results in impacted regions • Coronavirus reported cases by country • Surgeon surveys and insights from our field force • Epidemiology data combined with infectious diseases, economic and other scientific experts’ opinions ~20% of MD Sales ~60% of MD Sales ~20% of MD Sales Remaining Top 10 Markets: US, Italy, France, Germany, UK, Russia, Spain Key ASPAC Markets: China, Japan, Korea Rest of World Data Utilized 34 -- 34 of 40 -- Medical Devices: COVID-19 Framework 35 Approximately 1/3 of Procedures are Urgent or Non-Elective Franchise Urgent % Deferrable % Contact Lens N/A N/A Surgical Vision 10% 90% Biosurgery / Energy / General Surgery 40% 60% Endocutters 35% 65% ENT 10% 90% Aesthetics 5% 95% Hips / Knees / Other Ortho 10% 90% Spine 5% 95% Trauma 80% 20% Electrophysiology 10% 90% Stroke 80% 20% Total MD1 30% to 35% 65% to 70% 1 Excludes Contact Lens/Other -- 35 of 40 -- Medical Devices: COVID-19 Framework 36 Full Year 2020 Operational Sales Impact inclusive of Q1 Actuals: (-$4B) to (-$7B) Initial Impact Significant Impact Stabilization Recovery Q1 Q2 Q3 Q4 Countries Impacted: China, Japan, Korea • China represented more than 40% of total MD impact in Q1 • Japan and Korea represented less than 5% of total MD impact in Q1 • Impacts are less significant due to earlier timing and/or preventative measures taken – Deferrable procedures decline -20% to -60% – Urgent procedures decline -10% to -20% • Normalize and begin to recover pent-up demand – Deferrable procedures increase 0% to +15% – Urgent procedures normalize and are flat • Continue to recover pent-up demand but to a lesser extent – Deferrable procedures increase 0% to +10% – Urgent procedures are flat ~20% of MD Sales Major Markets: US, Italy, France, Germany, UK, Russia, Spain • U.S. represented ~30% of total MD impact in Q1 • Remaining major markets represented less than 20% of total MD impact in Q1 • Major markets seeing most significant impact to date – Deferrable procedures decline -65% to -85% – Urgent procedures decline -20% to -30% • Major markets begin to stabilize with declines slowing – Deferrable procedures decline -20% to -60% – Urgent procedures decline - 10% to -20% • Major markets normalize and begin to recover pent-up demand – Deferrable procedures increase 0% to +15% – Urgent procedures normalize and are flat ~60% of MD Sales Rest of World • ROW represented more than 5% of total MD impact in Q1 • Decline consistent with Major Markets • Decline consistent with Major Markets • Recovery consistent with Major Markets ~20% of MD Sales Overall economy, unemployment, insurance coverage and procedure capacity are key variables that could impact rate of recovery -- 36 of 40 -- 2020 Guidance 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Euro Average Rate: April 2020 = $1.09 37 April January Comments Adjusted Operational Sales1,2 (3.0%) - 0.5% 5.0% - 6.0% Operational Sales2 $79.2 - $82.2B (3.5%) - 0.0% $85.8 - $86.6B 4.5% - 5.5% Net Impact Acq./Div: ~0.5% Estimated Reported Sales 3 $77.5B - $80.5B (5.5%) - (2.0%) $85.4B - $86.2B 4.0% - 5.0% FX ($1.7B) or (2.0%) impact Adjusted Pre-Tax Operating Margin4,5 ~100 bps decline ~100 bps improvement Higher manufacturing costs partially offset by spending reductions Net Interest Expense / (Income) $50 - $150 million $0 - $100 million Lower rates on interest income earned Net Other Income4 $0.8 - $1.0 billion $1.5 - $1.7 billion Previously planned divestitures will be deferred Effective Tax Rate4 16.5% - 18.0% 17.5% - 18.5% Associated with sequence and pace of economic recovery Adjusted EPS (Operational)2,4 $7.65 - $8.05 (11.9%) - (7.3%) $9.00 - $9.15 3.7% - 5.4% Midpoint of $7.85 or (9.6%) Adjusted EPS (Reported)3,4 $7.50 - $7.90 (13.6%) – (9.0%) $8.95 - $9.10 3.1% - 4.8% Midpoint of $7.70 or (11.3%) FX ($0.15) or (1.7%) impact -- 37 of 40 -- Adjusted Reported3,4 $7.50 – $7.90 (13.6%) – (9.0%) 38 2020 EPS Guidance Update1 Adjusted Operational2,4 $7.65 – $8.05 (11.9%) – (7.3%) $9.03 $7.85 $7.70 1 Represents the midpoint of guidance 2 Excludes the impact of translational currency 3 Euro Average Rate: April 2020 = $1.09 4 Non-GAAP measure; excludes intangible amortization expense and special items Note: Values may not add due to rounding 3 $8.17 Base Business Net COVID-19 Impact ~(10%) $9.08 Other COVID-19 Related Impacts ~(3%) -- 38 of 40 -- Q&A Paul Stoffels, M.D. Vice Chairman of the Executive Committee & Chief Scientific Officer Chairman and Chief Executive Officer Alex Gorsky Joseph J. Wolk Executive Vice President, Chief Financial Officer Joaquin Duato Vice Chairman of the Executive Committee -- 39 of 40 -- -- 40 of 40 --